Eli Lilly and Company $LLY Stake Cut by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 0.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,333,220 shares of the company’s stock after selling 30,969 shares during the quarter. Eli Lilly and Company comprises approximately 30.1% of PNC Financial Services Group Inc.’s portfolio, making the stock its largest holding. PNC Financial Services Group Inc. owned about 0.05% of Eli Lilly and Company worth $55,166,785,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Hartford Funds Management Co LLC grew its stake in shares of Eli Lilly and Company by 74.6% in the 4th quarter. Hartford Funds Management Co LLC now owns 3,214 shares of the company’s stock valued at $3,456,000 after purchasing an additional 1,373 shares during the last quarter. McKinley Carter Wealth Services Inc. raised its stake in shares of Eli Lilly and Company by 17.9% during the fourth quarter. McKinley Carter Wealth Services Inc. now owns 7,206 shares of the company’s stock worth $7,745,000 after purchasing an additional 1,096 shares during the last quarter. Flynn Zito Capital Management LLC raised its stake in shares of Eli Lilly and Company by 117.3% during the fourth quarter. Flynn Zito Capital Management LLC now owns 2,143 shares of the company’s stock worth $2,304,000 after purchasing an additional 1,157 shares during the last quarter. Integral Investment Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 3.7% during the fourth quarter. Integral Investment Advisors Inc. now owns 4,075 shares of the company’s stock worth $4,379,000 after purchasing an additional 144 shares during the period. Finally, Profund Advisors LLC grew its position in Eli Lilly and Company by 22.4% in the 4th quarter. Profund Advisors LLC now owns 14,090 shares of the company’s stock valued at $15,142,000 after buying an additional 2,577 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary continue to highlight Eli Lilly’s leadership in the obesity boom, with strong sales momentum in key products such as Mounjaro and broader confidence that the company still has room to run. Article Title
• Positive Sentiment: Stat News reported that Eli Lilly tops prominent rankings for pharma R&D performance, reinforcing the view that the company’s pipeline and innovation engine remain among the best in the industry. Article Title
• Positive Sentiment: Eli Lilly also announced it completed a key olomorasib drug-interaction study, which helps clarify next steps for its KRAS pipeline and supports the long-term growth story beyond obesity drugs. Article Title
• Neutral Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations event that could provide more details on strategy and pipeline updates. Article Title
• Negative Sentiment: The U.S. Supreme Court declined to hear Eli Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million award and keeping legal/compliance risk in focus. Article Title
• Negative Sentiment: Related coverage noted that the ruling could raise scrutiny around Medicaid rebates and dividend implications, adding a modest overhang even as the core business remains strong. Article Title

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Leerink Partners dropped their price target on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a research note on Monday, April 27th. Guggenheim reissued a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Finally, The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,218.33.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,017.68 on Wednesday. The company has a market cap of $958.39 billion, a P/E ratio of 36.15, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The business has a fifty day moving average of $940.54 and a two-hundred day moving average of $1,000.84. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.